Compare MicroSectors FANG and Innovation 3X Leveraged ETN (FNGU) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MicroSectors FANG and Innovation 3X Leveraged ETN vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? MicroSectors FANG and Innovation 3X Leveraged ETN trades at $32.8 (market cap $2.94B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: MicroSectors FANG and Innovation 3X Leveraged ETN is far larger — about 3× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and MicroSectors FANG and Innovation 3X Leveraged ETN is trading nearer its 52-week high, Maravai LifeSciences Holdings Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold MicroSectors FANG and Innovation 3X Leveraged ETN for 20 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| FNGU | MRVI | |
|---|---|---|
Market Cap | $2.94B | $972.90M |
Volume | 1,823,720 | 4,325,710 |
Sector | Leveraged / Inverse | Health |
52-Week High | $37.20 | $9.00 |
52-Week Low | $13.73 | $2.83 |
Typical Hold Time | 20 Days | 0 Days |
Enterprise Value | — | $1.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FNGU, a 3X leveraged ETN tracking major tech stocks, trades at $36.69 with a slight 0.22% daily gain. Technical indicators show a bullish trend with strong moving average support, though RSI levels suggest potential overbought conditions. The ETN provides triple exposure to tech giants like Nvidia and Apple but carries significant volatility risks as highlighted by recent analysis of its 87% decline during previous market downturns.
The outlook remains tied to the performance of underlying tech stocks, offering amplified gains in bullish markets but severe losses during corrections. Key risks include leverage decay, concentration in mega-cap tech, and market volatility. Investors should weigh the potential for high returns against the substantial downside exposure inherent in leveraged products.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About MicroSectors FANG and Innovation 3X Leveraged ETN
FNGU is a leveraged ETN that seeks to provide three times (3x) the daily performance of top tech and innovation stocks. It is intended for traders seeking magnified short-term returns.
Read more on FNGU →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
